DE60327179D1 - Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten - Google Patents

Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten

Info

Publication number
DE60327179D1
DE60327179D1 DE60327179T DE60327179T DE60327179D1 DE 60327179 D1 DE60327179 D1 DE 60327179D1 DE 60327179 T DE60327179 T DE 60327179T DE 60327179 T DE60327179 T DE 60327179T DE 60327179 D1 DE60327179 D1 DE 60327179D1
Authority
DE
Germany
Prior art keywords
urea
derivatives
treatment
compound
eye diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327179T
Other languages
English (en)
Inventor
Vicken Karageozian
David Castillejos
John Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitreo Retinal Technologies Inc
Original Assignee
Vitreo Retinal Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitreo Retinal Technologies Inc filed Critical Vitreo Retinal Technologies Inc
Application granted granted Critical
Publication of DE60327179D1 publication Critical patent/DE60327179D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60327179T 2002-02-13 2003-02-13 Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten Expired - Lifetime DE60327179D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35734702P 2002-02-13 2002-02-13
US35757402P 2002-02-15 2002-02-15
PCT/US2003/004617 WO2003068166A2 (en) 2002-02-13 2003-02-13 Treatment of ophthalmic disorders using urea and urea derivatives

Publications (1)

Publication Number Publication Date
DE60327179D1 true DE60327179D1 (de) 2009-05-28

Family

ID=27737587

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327179T Expired - Lifetime DE60327179D1 (de) 2002-02-13 2003-02-13 Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten

Country Status (15)

Country Link
EP (1) EP1480678B1 (de)
JP (1) JP2005521681A (de)
KR (1) KR20040094687A (de)
CN (1) CN1633308A (de)
AT (1) ATE428412T1 (de)
AU (1) AU2003213084B2 (de)
BR (1) BR0307611A (de)
CA (1) CA2475338C (de)
DE (1) DE60327179D1 (de)
ES (1) ES2325360T3 (de)
IL (1) IL163374A (de)
MX (1) MXPA04007802A (de)
NZ (1) NZ535165A (de)
RU (1) RU2339369C2 (de)
WO (1) WO2003068166A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
EP1482922A4 (de) * 2002-03-14 2005-06-08 Vitreo Retinal Technologies In Mittel für die corneale oder intrastromale verabreichung zur behandlung oder prävention von erkrankungen des auges
AU2017313907B2 (en) * 2016-08-18 2022-11-24 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
KR20210020008A (ko) * 2018-06-11 2021-02-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 눈 질환을 치료하는 탈메틸화

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908063D0 (en) * 1989-04-11 1989-05-24 Beecham Group Plc Novel compounds
DK0705100T3 (da) * 1993-05-27 2003-11-17 Cenes Ltd Terapeutiske substituerede guanidiner
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
WO1995014461A1 (en) * 1993-11-23 1995-06-01 Cambridge Neuroscience, Inc. Therapeutic substituted guanidines
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
US6395758B1 (en) * 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
BR0008674A (pt) * 1999-03-02 2002-02-13 Vitreo Retinal Technologies In Método para tratar ou prevenir a proliferação de fibroblastos dentro do olho, tratar ou prevenir a neovascularização de tecidos oculares, acelerar a clarificação do sangue hemorrágico do humor vìtreo, causar a dissolução não-enzimática da interface hialóide e/ou causar a separação ou a desinserção do vìtreo posterior
US6337350B1 (en) * 1999-04-05 2002-01-08 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Also Published As

Publication number Publication date
EP1480678A4 (de) 2005-08-24
KR20040094687A (ko) 2004-11-10
CA2475338A1 (en) 2003-08-21
IL163374A (en) 2012-01-31
MXPA04007802A (es) 2005-04-19
CA2475338C (en) 2014-08-19
RU2339369C2 (ru) 2008-11-27
EP1480678A2 (de) 2004-12-01
BR0307611A (pt) 2004-12-21
WO2003068166A3 (en) 2003-12-24
JP2005521681A (ja) 2005-07-21
ES2325360T3 (es) 2009-09-02
ATE428412T1 (de) 2009-05-15
AU2003213084A1 (en) 2003-09-04
EP1480678B1 (de) 2009-04-15
CN1633308A (zh) 2005-06-29
RU2004127610A (ru) 2005-06-27
NZ535165A (en) 2006-08-31
AU2003213084B2 (en) 2008-06-26
WO2003068166A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE68902649T2 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE467616T1 (de) Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
NO962664D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
WO2005056524A3 (en) Therapeutic agents useful for treating pain
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
DE60220055D1 (de) 4-(4-methoxybenzyl)-n&#39;-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
DE60327179D1 (de) Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten
BRPI0412131A (pt) métodos de tratamento de distúrbios oftálmicos, para evitar hemorragia retìnica, perda de acuidade visual, reduzir exsudatos duros e retardar progressão de dano retìnico
BR0317714A (pt) Oxazóis como realçadores de mglur1
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
EA200501765A3 (ru) Средство для лечения болезней суставов

Legal Events

Date Code Title Description
8364 No opposition during term of opposition